The safety of H2-blockers use during pregnancy

Journal of Clinical Pharmacology

Volumn 50, Issue 1, 2010, Pages 81-87

  Matok, Ilan ^a   Gorodischer, Rafael ^a,c   Koren, Gideon ^a   Sheiner, Eyal ^b   Wiznitzer, Arnon ^c   Uziel, Elia ^d   Levy, Amalia ^e  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b Social Work Services   (Israel)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^d CLALIT HEALTH SERVICES   (Israel)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Data bases; Drug safety; H2 blockers; Linkage; Pregnancy

Indexed keywords

CIMETIDINE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; RANITIDINE;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DATA BASE; DRUG SAFETY; DRUG USE; ETHNIC GROUP; FEMALE; FEVER; FIRST TRIMESTER PREGNANCY; HEALTH MAINTENANCE ORGANIZATION; HOSPITALIZATION; HUMAN; ISRAEL; MATERNAL AGE; MATERNAL DIABETES MELLITUS; MEDICAL RECORD; MOTHER; PARITY; PREGNANCY TERMINATION; PUBLIC HOSPITAL; RISK; SMOKING;

ABNORMALITIES, DRUG-INDUCED; ABORTION, THERAPEUTIC; ADOLESCENT; ADULT; APGAR SCORE; CIMETIDINE; COHORT STUDIES; FAMOTIDINE; FEMALE; HISTAMINE H2 ANTAGONISTS; HUMANS; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; MATERNAL-FETAL EXCHANGE; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; MIDDLE AGED; PERINATAL MORTALITY; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTER, FIRST; PREMATURE BIRTH; RANITIDINE; RETROSPECTIVE STUDIES;

EID: 72749105408     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009350483     Document Type: Article

References (33)

1. Baron TH, Ramirez B., Richter JE Gastrointestinal motility disorders during pregnancy. Ann Intern Med. 1993 ; 118: 366-375.
2. Brzana RJ, Koch KL Intractable nausea presenting as gastroesophageal reflux disease. Ann Intern Med. 1997 ; 126: 704-707.
3. Better news on population. Lancet. 1992 ;339: 1600.
4. Howe JP, McGowan WA, Moore J., McCaughey W., Dundee JW The placental transfer of cimetidine. Anaesthesia. 1981 ; 36: 371-375.
5. Zantac [product information]. Zantac. Brentford, UK: Glaxo Wellcome ; 2000.
6. Higasha N, Kamada S, Sakanova M, Takeuchi M, Simpo K, Tanable T. Teratogenicity studies in rats and rabbits. J Toxol Sci. 1984;9:53-72. As cited in Shepard TH. Catalog of Teratogenic Agents. 6th ed. Baltimore: Johns Hopkins University Press; 1989:550.
7. 2 receptor antagonists. Am J Perinatol. 1991 ; 8: 37-38.
8. 2-blockers: a prospective cohort study. Dig Dis Sci. 1996 ; 41: 1145-1149.
9. K?Currency signll?©n B. Delivery outcome after the use of acid-suppressing drugs in early pregnancy with special reference to omeprazole. Br J Obstet Gynaecol. 1998 ; 105: 877-881.
10. Ruig?3mez A., Garc?a Rodr?guez LA, Cattaruzzi C., et al. Use of cimetidine, omeprazole, and ranitidine in pregnant women and pregnancy outcomes. Am J Epidemiol. 1999 ; 150: 476-481.
11. F. Rosa, personal communication, FDA 1993. In: Briggs GG, Freeman RK, Yaffe SJ, eds. Drugs in Pregnancy and Lactation. 7 th ed. Baltimore: Williams & Wilkins ; 2005: 627-628.
12. 2-blockers: a collaborative study of the European Network of Teratology Information Services. Reprod Toxicol. 2005 ; 19: 453-458.
13. Schwethelm B., Margolis LH, Miller C., Smith S. Risk status and pregnancy outcome among Medicaid recipients. Am J Prev Med. 1989 ; 5: 157-163.
14. Smallwood RA, Berl RG, Castagnoli N., et al. Safety of acid-suppressing drugs. Dig Dis Sci. 2005 ; 40: 63S - 80S.
15. Central Bureau of Statistics. Statistical Abstract of Israel 2007: No. 58. Localities and Population by District, Subdistrict and Type of Locality. Available at http://www.cbs.gov.il/shnaton58/st02-08.pdf. Accessed June 14, 2008.
16. Central Bureau of Statistics, State of Israel. Hoda?a laitonut [in Hebrew]. Available at http//www.cbs.gov.il/reader/newhodaot/searh-text-hodaot. html. Accessed November 25, 2008.
17. World Health Organization (WHO). Collaborating Centre for Drug Statistics Methodology. Available at http://www.whocc.no/atcddd/. Accessed November 5, 2008.
18. Centers for Disease Control and Prevention. Metropolitan Atlanta Congenital Defects Program Coding Manual. Available at http://www.cdc.gov/ ncbddd/bd/macdp.htm. Accessed November 5, 2008.
19. Rasmussen SA, Olney RS, Holmes LB, Lin AE, Keppler-Noreuil KM Guidelines for case classification for the National Birth Defects Prevention Study. Birth Defects Res. 2003 ; 67: 193-201.
20. Correa-Villasenor A., Cragan J., Kucik J., O?Leary L., Siffel C., Williams L. The Metropolitan Atlanta Congenital Defects Program: 35 years of birth defects surveillance at the Centers for Disease Control and Prevention. Birth Defects Res A Clin Mol Teratol. 2003 ; 67: 617-624.
21. Sheiner E., Shoham-Vardi I., Sheiner EK, Mazor M., Katz M., Carmi R. Maternal factors associated with severity of birth defects. Int J Gynaecol Obstet. 1999 ; 64: 227-232.
22. Sheiner E., Shoham-Vardi I., Weitzman D., Gohar J., Carmi R. Decisions regarding pregnancy termination among Bedouin couples referred to third level ultrasound clinic. Eur J Obstet Gynecol Reprod Biol. 1998 ; 76: 141-146.
23. Say B., Barber N., Chambers C. A case of MURCS association after exposure to cimetidine in utero. Pediatr Res. 1985 ; 19: 329A.
24. Larson JD, Patatanian E., Miner PB, Rayburn WF, Robinson MG Double-blind, placebo-controlled study of ranitidine for gastroesophageal reflux symptoms during pregnancy. Obstet Gynecol. 1997 ; 90: 83-87. (Pubitemid 27272962)
25. Rayburn W., Liles E., Christensen H., Robinson M. Antacids vs antacids plus non-prescription ranitidine for heartburn during pregnancy. Int J Gynecol Obstet. 1999 ; 66: 35-37.
26. Colin Jones DG, Langman MJ, Lawson DH, et al. Post-marketing surveillance of the safety of cimetidine: twelve-month morbidity report. Q J Med. 1985 ; 54: 253-268.
27. Reefhuis J., Honein M. Maternal age and non-chromosomal birth defects, Atlanta-1968-2000: teenager or thirty-something, who is at risk? Birth Defects Res A Clin Mol Teratol. 70: 572-579.
28. Blank A., Grave G., Metzger BE Effects of gestational diabetes on perinatal morbidity reassessed: report of the International Workshop on Adverse Perinatal Outcomes of Gestational Diabetes Mellitus, December 3-4, 1992. Diabetes Care. 1995 ; 18: 127-129.
29. Meyerovitch J., Sherf M., Antebi F., et al. The incidence of anemia in an Israeli population: a population analysis for anemia in 34,512 Israeli infants aged 9 to 18 months. Pediatrics. 2006 ; 118: 1055-1060.
30. Ray WA, Griffin MR Use of Medicaid data for pharmacoepidemiology. Am J Epidemiol. 1989 ; 129: 837-849.
31. West SL, Savitz DA, Koch G., Strom BL, Guess HA, Hartzema A. Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol. 1995 ; 142: 1103-1112.
32. Johnson RE, Vollmer WM Comparing sources of drug data about the elderly. J Am Geriatr Soc. 1991 ; 39: 1079-1084.
33. De Jong van den Berg LT, Feenstra N., Sorensen HT, Cornel MC Improvement of drug exposure data in a registration of congenital anomalies. Pilot-study: pharmacist and mother as sources for drug exposure data during pregnancy. EuroMAP Group. European Medicine and Pregnancy Group. Teratology. 1999 ; 60: 33-36.